865 related articles for article (PubMed ID: 33704443)
1. Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease.
Thomas GEC; Zarkali A; Ryten M; Shmueli K; Gil-Martinez AL; Leyland LA; McColgan P; Acosta-Cabronero J; Lees AJ; Weil RS
Brain; 2021 Jul; 144(6):1787-1798. PubMed ID: 33704443
[TBL] [Abstract][Full Text] [Related]
2. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic profiles in Parkinson's disease.
Kurvits L; Lättekivi F; Reimann E; Kadastik-Eerme L; Kasterpalu KM; Kõks S; Taba P; Planken A
Exp Biol Med (Maywood); 2021 Mar; 246(5):584-595. PubMed ID: 33148011
[TBL] [Abstract][Full Text] [Related]
4. Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease.
Zarkali A; McColgan P; Ryten M; Reynolds R; Leyland LA; Lees AJ; Rees G; Weil RS
Brain; 2020 Dec; 143(11):3435-3448. PubMed ID: 33118028
[TBL] [Abstract][Full Text] [Related]
5. Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI.
Ahmadi SA; Bötzel K; Levin J; Maiostre J; Klein T; Wein W; Rozanski V; Dietrich O; Ertl-Wagner B; Navab N; Plate A
Neuroimage Clin; 2020; 26():102185. PubMed ID: 32050136
[TBL] [Abstract][Full Text] [Related]
6. Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.
Guan X; Xuan M; Gu Q; Huang P; Liu C; Wang N; Xu X; Luo W; Zhang M
NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 26853890
[TBL] [Abstract][Full Text] [Related]
7. Different iron deposition patterns in early- and middle-late-onset Parkinson's disease.
Xuan M; Guan X; Gu Q; Shen Z; Yu X; Qiu T; Luo X; Song R; Jiaerken Y; Xu X; Huang P; Luo W; Zhang M
Parkinsonism Relat Disord; 2017 Nov; 44():23-27. PubMed ID: 28838722
[TBL] [Abstract][Full Text] [Related]
8. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
[TBL] [Abstract][Full Text] [Related]
9. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
[TBL] [Abstract][Full Text] [Related]
10. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention.
Olivieri S; Conti A; Iannaccone S; Cannistraci CV; Campanella A; Barbariga M; Codazzi F; Pelizzoni I; Magnani G; Pesca M; Franciotta D; Cappa SF; Alessio M
J Neurosci; 2011 Dec; 31(50):18568-77. PubMed ID: 22171055
[TBL] [Abstract][Full Text] [Related]
11. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
[TBL] [Abstract][Full Text] [Related]
12. Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins.
Anderson G; Maes M
Mol Neurobiol; 2014 Apr; 49(2):771-83. PubMed ID: 24085563
[TBL] [Abstract][Full Text] [Related]
13. [Susceptibility-weighted imaging in detecting brain iron accumulation of Parkinson's disease].
Huang XM; Sun B; Xue YJ; Duan Q
Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(43):3054-8. PubMed ID: 21211325
[TBL] [Abstract][Full Text] [Related]
14. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage.
Flønes IH; Fernandez-Vizarra E; Lykouri M; Brakedal B; Skeie GO; Miletic H; Lilleng PK; Alves G; Tysnes OB; Haugarvoll K; Dölle C; Zeviani M; Tzoulis C
Acta Neuropathol; 2018 Mar; 135(3):409-425. PubMed ID: 29270838
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic signatures of brain regional vulnerability to Parkinson's disease.
Keo A; Mahfouz A; Ingrassia AMT; Meneboo JP; Villenet C; Mutez E; Comptdaer T; Lelieveldt BPF; Figeac M; Chartier-Harlin MC; van de Berg WDJ; van Hilten JJ; Reinders MJT
Commun Biol; 2020 Mar; 3(1):101. PubMed ID: 32139796
[TBL] [Abstract][Full Text] [Related]
16. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2.
Barbosa JH; Santos AC; Tumas V; Liu M; Zheng W; Haacke EM; Salmon CE
Magn Reson Imaging; 2015 Jun; 33(5):559-65. PubMed ID: 25721997
[TBL] [Abstract][Full Text] [Related]
17. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease.
Bunzeck N; Singh-Curry V; Eckart C; Weiskopf N; Perry RJ; Bain PG; Düzel E; Husain M
Parkinsonism Relat Disord; 2013 Dec; 19(12):1136-42. PubMed ID: 24025315
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
[TBL] [Abstract][Full Text] [Related]
19. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
[TBL] [Abstract][Full Text] [Related]
20. Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson's disease.
Friedrich I; Reimann K; Jankuhn S; Kirilina E; Stieler J; Sonntag M; Meijer J; Weiskopf N; Reinert T; Arendt T; Morawski M
Acta Neuropathol Commun; 2021 Mar; 9(1):47. PubMed ID: 33752749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
